366017-26-7

Upstream product

• 366016-66-2 4-(chloromethyl)-2-[(E)-2-[4-(trifluoromethyl)-phenyl]ethenyl]-1,3-oxazole 
• 366016-89-9 4-{4-[2-(2-Hydroxyethyl)-1H-imidazol-1-yl]butyl}phenol 

Downstream Products

• 511532-68-6 2-[2-[1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]ethyl]-1H-isoindole-1,3(2H)-dione 
• 511532-21-1 2-[1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]ethyl isopropylcarbamate 
• 511532-66-4 (E)-2-(1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-imidazol-2-yl)ethanamine 
• 511532-22-2 2-[1-[4-[4-[[2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]butyl]-1H-imidazol-2-yl]ethyl methylcarbamate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF

This invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by the formula: wherein m is an integer of 1 to 3; n is an integer of 1 or 2; R1 is a halogen atom or an optionally halogenated C

MEDICINAL COMPOSITIONS IMPROVED IN SOLUBLITY IN WATER

Solid dispersions are provided comprising an HER2 inhibitor which is hardly or not soluble in water and a hydrophilic polymer. These solid dispersions have been improved in the solubility of the HER2 inhibitor, oral absorption and bioavailability in blood

MEDICINAL COMPOSITIONS HAVING IMPROVED ABSORBABILITY

An HER2 inhibitor having an average particle size of about 3 μm or less or a composition containing the same which has improved HER2 inhibitor-absorbability.